Lineage Cell's Dry AMD Gene Therapy Demonstrate Functional, Anatomical Improvements

Lineage Cell Therapeutics Inc LCTX reported updated interim results from its Phase 1/2a study of its lead product candidate, OpRegen cell therapy for dry age-related macular degeneration (AMD) with geographic atrophy (GA).
Overall, 10/12 (83%) of the Cohort 4 patients' treated eyes continued to be at or above baseline visual acuity at their last assessment, ranging from six months to approximately three years post-transplant.
Improvements in best-corrected visual acuity for Cohort 4 patients reached up to +19 letters.
In contrast, 10/12 (83%) of the patients' untreated eyes were below pre-treatment baseline values at the same time points.
Three patients with evidence of retinal tissue restoration continue to demonstrate areas of repair and sustained visual acuity improvements as of their last clinical visit.
One patient with confirmed atrophy growth at baseline has had zero progression for almost three full years.
The Company intends to meet with the FDA in Q4 of 2021 to discuss the clinical development plan for OpRegen.
Evidence of durable engraftment of OpRegen RPE cells has extended to more than five years in the earliest treated patients, supporting the potential for OpRegen to be a one-time treatment.
Price Action: LCTX shares are up 3.88% at $2.68 during the market session on the last check Tuesday.